Table 5.
Baseline characteristics of patients with LS-SCLC and ILA in this study
| Variable | First-line treatment | ||
|---|---|---|---|
| Chemoradiotherapy | Chemotherapy | P value | |
| (n = 25) | (n = 24) | ||
| Age, ≥ 70/ < 70 years | 16/9 | 18/6 | 0.5380 |
| Sex, male/female | 21/4 | 20/4 | 1.0000 |
| ECOG-PS, 0/1/2 (0 vs. 1 or 2) | 15/10/0 | 10/11/3 | 0.2578 |
| Clinical stagea, I/II/III (I vs. II/III) | 1/1/23 | 1/5/18 | 1.0000 |
| Brinkmann index, ≥ 400/ < 400 | 24/1 | 23/1 | 1.0000 |
| Proportion of ILA area of any lung zone, 5%/10%/15–30%/30–50% (5%/10% vs. 15–30%/30–50%) | 13/11/1/0 | 9/7/7/1 | 0.0106 |
| V20, median (range), % | 22 (10–32) | ||
aClinical staging was according to the 7th edition of the TNM classification of lung cancer [9]. LS-SCLC, limited-stage small-cell lung cancer
ECOG-PS, Eastern Cooperative Oncology Group performance status; ILA, interstitial lung abnormality; V20, percentage of normal lung receiving at least 20 Gy